![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in pat... Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. Show more
Aileron Therapeutics to be Included in the Russell Microcap® Index PR Newswire AUSTIN, Texas, July 1, 2024 AUSTIN, Texas, July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the...
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.24 | -8.19112627986 | 2.93 | 3.13 | 2.6 | 47448 | 2.82275771 | CS |
4 | -0.31 | -10.3333333333 | 3 | 3.3 | 2.6 | 71752 | 2.97002233 | CS |
12 | -2.3 | -46.0921843687 | 4.99 | 5 | 2.6 | 89415 | 3.44506233 | CS |
26 | -1.64 | -37.8752886836 | 4.33 | 7.42 | 2.6 | 77543 | 4.26950192 | CS |
52 | 0.81 | 43.085106383 | 1.88 | 7.42 | 1.01 | 75095 | 3.74553661 | CS |
156 | -19.31 | -87.7727272727 | 22 | 25.4 | 1.01 | 290043 | 9.24250548 | CS |
260 | -8.516 | -75.9950026771 | 11.206 | 49.4 | 1.01 | 618032 | 22.86590937 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions